JP2016507066A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016507066A5 JP2016507066A5 JP2015557128A JP2015557128A JP2016507066A5 JP 2016507066 A5 JP2016507066 A5 JP 2016507066A5 JP 2015557128 A JP2015557128 A JP 2015557128A JP 2015557128 A JP2015557128 A JP 2015557128A JP 2016507066 A5 JP2016507066 A5 JP 2016507066A5
- Authority
- JP
- Japan
- Prior art keywords
- fragment
- subject
- biological sample
- polypeptide
- amount
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000012634 fragment Substances 0.000 claims description 138
- 239000012472 biological sample Substances 0.000 claims description 128
- 238000000034 method Methods 0.000 claims description 109
- BGFTWECWAICPDG-UHFFFAOYSA-N 2-[bis(4-chlorophenyl)methyl]-4-n-[3-[bis(4-chlorophenyl)methyl]-4-(dimethylamino)phenyl]-1-n,1-n-dimethylbenzene-1,4-diamine Chemical compound C1=C(C(C=2C=CC(Cl)=CC=2)C=2C=CC(Cl)=CC=2)C(N(C)C)=CC=C1NC(C=1)=CC=C(N(C)C)C=1C(C=1C=CC(Cl)=CC=1)C1=CC=C(Cl)C=C1 BGFTWECWAICPDG-UHFFFAOYSA-N 0.000 claims description 103
- 102000006942 B-Cell Maturation Antigen Human genes 0.000 claims description 97
- 108010008014 B-Cell Maturation Antigen Proteins 0.000 claims description 97
- 229920001184 polypeptide Polymers 0.000 claims description 96
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 96
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 96
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 60
- 239000006228 supernatant Substances 0.000 claims description 49
- 230000004083 survival effect Effects 0.000 claims description 48
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims description 47
- 210000002966 serum Anatomy 0.000 claims description 46
- 239000000523 sample Substances 0.000 claims description 45
- 238000003556 assay Methods 0.000 claims description 41
- 238000001514 detection method Methods 0.000 claims description 41
- 201000000050 myeloid neoplasm Diseases 0.000 claims description 41
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims description 40
- 238000003018 immunoassay Methods 0.000 claims description 36
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims description 35
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims description 35
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 claims description 34
- 210000001185 bone marrow Anatomy 0.000 claims description 32
- 210000005087 mononuclear cell Anatomy 0.000 claims description 32
- 238000002965 ELISA Methods 0.000 claims description 24
- 238000003127 radioimmunoassay Methods 0.000 claims description 24
- 208000034578 Multiple myelomas Diseases 0.000 claims description 19
- 208000028564 B-cell non-Hodgkin lymphoma Diseases 0.000 claims description 17
- 238000012286 ELISA Assay Methods 0.000 claims description 17
- 102000004190 Enzymes Human genes 0.000 claims description 12
- 108090000790 Enzymes Proteins 0.000 claims description 12
- 230000002055 immunohistochemical effect Effects 0.000 claims description 10
- 238000012544 monitoring process Methods 0.000 claims description 8
- 238000004393 prognosis Methods 0.000 claims description 6
- 239000003153 chemical reaction reagent Substances 0.000 claims description 4
- 210000002798 bone marrow cell Anatomy 0.000 claims description 2
- 238000003364 immunohistochemistry Methods 0.000 claims description 2
- 230000002250 progressing effect Effects 0.000 description 4
- 238000004113 cell culture Methods 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361762753P | 2013-02-08 | 2013-02-08 | |
| US61/762,753 | 2013-02-08 | ||
| PCT/US2014/015338 WO2014124280A1 (en) | 2013-02-08 | 2014-02-07 | Improved diagnostic, prognostic, and monitoring methods for multiple myeloma, chronic lymphocytic leukemia, and b-cell non-hodgkin lymphoma |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018090456A Division JP2018136344A (ja) | 2013-02-08 | 2018-05-09 | 多発性骨髄腫、慢性リンパ球性白血病、およびｂ細胞非ホジキンリンパ腫の改善された診断方法、予後予測方法、およびモニタリング方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016507066A JP2016507066A (ja) | 2016-03-07 |
| JP2016507066A5 true JP2016507066A5 (enExample) | 2017-03-09 |
Family
ID=51300158
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015557128A Withdrawn JP2016507066A (ja) | 2013-02-08 | 2014-02-07 | 多発性骨髄腫、慢性リンパ球性白血病、およびｂ細胞非ホジキンリンパ腫の改善された診断方法、予後予測方法、およびモニタリング方法 |
| JP2018090456A Pending JP2018136344A (ja) | 2013-02-08 | 2018-05-09 | 多発性骨髄腫、慢性リンパ球性白血病、およびｂ細胞非ホジキンリンパ腫の改善された診断方法、予後予測方法、およびモニタリング方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018090456A Pending JP2018136344A (ja) | 2013-02-08 | 2018-05-09 | 多発性骨髄腫、慢性リンパ球性白血病、およびｂ細胞非ホジキンリンパ腫の改善された診断方法、予後予測方法、およびモニタリング方法 |
Country Status (5)
| Country | Link |
|---|---|
| US (2) | US10126301B2 (enExample) |
| EP (1) | EP2954330A4 (enExample) |
| JP (2) | JP2016507066A (enExample) |
| CA (1) | CA2900529A1 (enExample) |
| WO (1) | WO2014124280A1 (enExample) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2016507066A (ja) | 2013-02-08 | 2016-03-07 | インスティテュート フォー ミエローマ アンド ボーン キャンサー リサーチ | 多発性骨髄腫、慢性リンパ球性白血病、およびｂ細胞非ホジキンリンパ腫の改善された診断方法、予後予測方法、およびモニタリング方法 |
| US11353458B2 (en) | 2015-10-30 | 2022-06-07 | Glaxosmithkline Intellectual Property Development Limited | Prognostic method |
| EP3402515B8 (en) | 2016-01-12 | 2021-12-08 | Oncotracker, Inc. | Improved methods for monitoring immune status of a subject |
| US20200326339A1 (en) | 2016-05-16 | 2020-10-15 | James Richard BERENSON | Improved methods for monitoring immune status of a subject |
| KR20190116420A (ko) | 2017-02-17 | 2019-10-14 | 프레드 헛친슨 켄서 리서치 센터 | Bcma 관련 암 및 자가면역 장애의 치료를 위한 조합 요법 |
| US20230059544A1 (en) * | 2017-02-28 | 2023-02-23 | Menarini Silicon Biosystems, S.p.A. | Kits and assays to detect circulating multiple myeloma cells from blood |
| EP3639028B1 (en) | 2017-06-13 | 2025-10-15 | Onco Tracker, Inc. | Diagnostic, prognostic, and monitoring methods for breast cancer |
| ES2644580B2 (es) * | 2017-07-26 | 2018-06-04 | Universitat Politècnica De València | Procedimiento de diagnóstico de lupus eritematoso sistémico (les) |
| WO2019035938A1 (en) | 2017-08-16 | 2019-02-21 | Elstar Therapeutics, Inc. | MULTISPECIFIC MOLECULES BINDING TO BCMA AND USES THEREOF |
| CN111886012A (zh) | 2017-11-06 | 2020-11-03 | 朱诺治疗学股份有限公司 | 细胞疗法与γ分泌酶抑制剂的组合 |
| WO2019139987A1 (en) | 2018-01-09 | 2019-07-18 | Elstar Therapeutics, Inc. | Calreticulin binding constructs and engineered t cells for the treatment of diseases |
| US12152073B2 (en) | 2018-03-14 | 2024-11-26 | Marengo Therapeutics, Inc. | Multifunctional molecules that bind to calreticulin and uses thereof |
| CA3098420A1 (en) | 2018-06-01 | 2019-12-05 | Novartis Ag | Binding molecules against bcma and uses thereof |
| CN112955465A (zh) | 2018-07-03 | 2021-06-11 | 马伦戈治疗公司 | 抗tcr抗体分子及其用途 |
| JP7577647B2 (ja) * | 2018-08-31 | 2024-11-05 | エフ． ホフマン－ラ ロシュ アーゲー | Ｄｌｂｃｌについての予後指標におけるチミジンキナーゼ（ｔｋ－１） |
| CN114026122B (zh) | 2019-02-21 | 2024-12-31 | 马伦戈治疗公司 | 结合t细胞相关癌细胞的多功能分子及其用途 |
| CN119039441A (zh) | 2019-02-21 | 2024-11-29 | 马伦戈治疗公司 | 与nkp30结合的抗体分子及其用途 |
| CR20210576A (es) | 2019-05-21 | 2021-12-15 | Novartis Ag | Moléculas de unión a cd19 y usos de las mismas |
| CN116234829A (zh) | 2020-01-03 | 2023-06-06 | 马伦戈治疗公司 | 抗tcr抗体分子及其用途 |
| BR112023020832A2 (pt) | 2021-04-08 | 2023-12-19 | Marengo Therapeutics Inc | Moléculas multifuncionais ligadas a tcr e seus usos |
| CN117305458B (zh) * | 2023-10-20 | 2024-06-21 | 四川省医学科学院·四川省人民医院 | TKTmRNA检测试剂在制备多发性骨髓瘤筛查试剂盒中的用途及试剂盒 |
Family Cites Families (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4493795A (en) | 1983-10-17 | 1985-01-15 | Syntex (U.S.A.) Inc. | Synthetic peptide sequences useful in biological and pharmaceutical applications and methods of manufacture |
| US5629327A (en) | 1993-03-01 | 1997-05-13 | Childrens Hospital Medical Center Corp. | Methods and compositions for inhibition of angiogenesis |
| DE69733694T2 (de) | 1996-07-10 | 2006-07-06 | Muramatsu, Takashi, Nagoya | Verwendung von proteinen aus der mk familie als hämatopoietischer faktor |
| GB9704444D0 (en) * | 1997-03-04 | 1997-04-23 | Isis Innovation | Non-invasive prenatal diagnosis |
| US6355623B2 (en) * | 1998-09-24 | 2002-03-12 | Hopital-Sainte-Justine | Method of treating IBD/Crohn's disease and related conditions wherein drug metabolite levels in host blood cells determine subsequent dosage |
| US20040002068A1 (en) * | 2000-03-01 | 2004-01-01 | Corixa Corporation | Compositions and methods for the detection, diagnosis and therapy of hematological malignancies |
| AU2002306596B2 (en) | 2001-02-27 | 2008-01-17 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Analogs of thalidomide as potential angiogenesis inhibitors |
| CA2459890A1 (en) | 2001-09-06 | 2003-03-20 | Biogen Idec Ma Inc. | Crystal structure of baff, and use thereof in drug design |
| CA2523776A1 (en) | 2003-03-07 | 2004-09-23 | Xencor, Inc. | Baff mutants with at least one amino acid substitution and methods of their production |
| WO2006025345A1 (ja) | 2004-08-31 | 2006-03-09 | Kowa Company, Ltd. | 抗ヒトｂａｆｆ抗体 |
| EP1814577B1 (en) | 2004-10-13 | 2014-04-23 | The Washington University | Use of baff to treat sepsis |
| JP2008525002A (ja) | 2004-12-23 | 2008-07-17 | ラボラトワール セローノ ソシエテ アノニム | Ｂｃｍａポリペプチド及びその使用 |
| WO2007039489A1 (en) * | 2005-09-26 | 2007-04-12 | Apotech Corporation | Antibodies against april as biomarkers for early prognosis of lymphoma patients |
| WO2007053732A2 (en) * | 2005-11-01 | 2007-05-10 | Mayo Foundation For Medical Education And Research | Promoter polymorphisms of the blys gene and use in diagnostic methods |
| WO2007056288A2 (en) * | 2005-11-08 | 2007-05-18 | Biogen Idec Ma Inc. | Methods of evaluating baff |
| CA2629306A1 (en) | 2005-11-23 | 2007-05-31 | Genentech, Inc. | Methods and compositions related to b cell assays |
| SI1966202T1 (sl) | 2005-12-13 | 2012-01-31 | Incyte Corp | S heteroarilom substituirani pirolo (2,3-b)piridini in pirolo (2,3-b)pirimidini kot zaviralci janus kinaze |
| US20080058316A1 (en) | 2006-02-27 | 2008-03-06 | The Johns Hopkins University | Cancer treatment with gama-secretase inhibitors |
| PT2016102E (pt) | 2006-05-03 | 2012-05-15 | Us Gov Health & Human Serv | Recetores de célula t quimérica e materiais relacionados e métodos de uso |
| EP2173752B2 (en) | 2007-06-13 | 2022-07-13 | Incyte Holdings Corporation | Salts of the janus kinase inhibitor (r)-3-(4-(7h-pyrrolo(2,3-d)pyrimidin-4-yl)-1h-pyrazol-1-yl)-3-cyclopentylpropanenitrile |
| JP5739326B2 (ja) | 2008-04-25 | 2015-06-24 | ザイモジェネティクス， インコーポレイテッド | Ｂ細胞上でのｂｃｍａタンパク発現レベル及び診断法における使用 |
| DK2406284T5 (en) | 2009-03-10 | 2017-06-12 | Biogen Ma Inc | ANTI-BCMA ANTIBODIES |
| US9101559B2 (en) | 2009-05-08 | 2015-08-11 | New York University | Leukemic cell CNS infiltration controlled by notch-induced chemotaxis |
| US20130101599A1 (en) * | 2011-04-21 | 2013-04-25 | Boehringer Ingelheim International Gmbh | Bcma-based stratification and therapy for multiple myeloma patients |
| EA201790330A1 (ru) * | 2011-05-27 | 2018-02-28 | Глаксо Груп Лимитед | Белки, связывающиеся с bcma (cd269/tnfrsf17) |
| EP2914628A1 (en) | 2012-11-01 | 2015-09-09 | Max-Delbrück-Centrum für Molekulare Medizin | An antibody that binds cd269 (bcma) suitable for use in the treatment of plasma cell diseases such as multiple myeloma and autoimmune diseases |
| EP2762496A1 (en) | 2013-02-05 | 2014-08-06 | EngMab AG | Method for the selection of antibodies against BCMA |
| JP2016507066A (ja) | 2013-02-08 | 2016-03-07 | インスティテュート フォー ミエローマ アンド ボーン キャンサー リサーチ | 多発性骨髄腫、慢性リンパ球性白血病、およびｂ細胞非ホジキンリンパ腫の改善された診断方法、予後予測方法、およびモニタリング方法 |
| JP2017503001A (ja) | 2014-01-20 | 2017-01-26 | ギリアード サイエンシーズ， インコーポレイテッド | がんを処置するための療法 |
| US10144782B2 (en) | 2014-04-30 | 2018-12-04 | Max-Delbrück-Centrum Für Molekulare Medizin In Der Helmholtz-Gemeinschaft | Humanized antibodies against CD269 (BCMA) |
| US10363260B2 (en) | 2014-05-28 | 2019-07-30 | Oncotracker, Inc. | Anti-cancer effects of JAK2 inhibitors in combination with thalidomide derivatives and glucocorticoids |
| WO2015191668A1 (en) | 2014-06-10 | 2015-12-17 | Institute For Myeloma & Bone Cancer Research | Anti-cancer effects of proteasome inhibitors in combination with glucocorticoids, arsenic containing compounds, and ascorbic acid |
| SMT202200285T1 (it) | 2014-08-11 | 2022-09-14 | Acerta Pharma Bv | Combinazioni terapeutiche di un inibitore di btk, un inibitore di pd-1 e/o un inibitore di pd-l1 |
| US9988452B2 (en) | 2014-10-14 | 2018-06-05 | Novartis Ag | Antibody molecules to PD-L1 and uses thereof |
| JP6997620B2 (ja) | 2014-12-05 | 2022-02-04 | メモリアル スローン ケタリング キャンサー センター | Ｂ細胞成熟抗原を標的化するキメラ抗原受容体およびその使用 |
| US11060150B2 (en) | 2015-03-17 | 2021-07-13 | Mayo Foundation For Medical Education And Research | Methods and materials for assessing and treating cancer |
| EP3662909A1 (en) | 2015-07-24 | 2020-06-10 | Oncotracker, Inc. | Gamma secretase modulators for the treatment of immune system dysfunction |
| JO3799B1 (ar) | 2015-08-17 | 2021-01-31 | Janssen Pharmaceutica Nv | الأجسام المضادة ل bcma، جزيئات ربط الانتيجين ثنائية التحديد التي تربط bcma و cd3، و استخداماتها |
| US11353458B2 (en) | 2015-10-30 | 2022-06-07 | Glaxosmithkline Intellectual Property Development Limited | Prognostic method |
| EP3402515B8 (en) | 2016-01-12 | 2021-12-08 | Oncotracker, Inc. | Improved methods for monitoring immune status of a subject |
| US20200326339A1 (en) | 2016-05-16 | 2020-10-15 | James Richard BERENSON | Improved methods for monitoring immune status of a subject |
| EP3490590A2 (en) | 2016-08-01 | 2019-06-05 | Novartis AG | Treatment of cancer using a chimeric antigen receptor in combination with an inhibitor of a pro-m2 macrophage molecule |
| WO2018085363A2 (en) | 2016-11-02 | 2018-05-11 | Berenson James Richard | Cd147 detection in diagnostic, prognostic and monitoring methods for multiple myeloma |
| EP3639028B1 (en) | 2017-06-13 | 2025-10-15 | Onco Tracker, Inc. | Diagnostic, prognostic, and monitoring methods for breast cancer |
| JP2020528885A (ja) | 2017-07-19 | 2020-10-01 | フェイト セラピューティクス，インコーポレイテッド | 養子免疫療法における免疫細胞調節のための組成物および方法 |
| WO2020092792A2 (en) | 2018-10-31 | 2020-05-07 | Oncotracker, Inc. | Method of enhancing immune-based therapy |
-
2014
- 2014-02-07 JP JP2015557128A patent/JP2016507066A/ja not_active Withdrawn
- 2014-02-07 CA CA2900529A patent/CA2900529A1/en not_active Abandoned
- 2014-02-07 WO PCT/US2014/015338 patent/WO2014124280A1/en not_active Ceased
- 2014-02-07 EP EP14748765.6A patent/EP2954330A4/en not_active Withdrawn
- 2014-02-07 US US14/766,694 patent/US10126301B2/en active Active
-
2018
- 2018-05-09 JP JP2018090456A patent/JP2018136344A/ja active Pending
- 2018-09-28 US US16/146,300 patent/US12174189B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016507066A5 (enExample) | ||
| AU2013210776B2 (en) | Biomarkers for gastric cancer and uses thereof | |
| Szczudlik et al. | Antititin antibody in early‐and late‐onset myasthenia gravis | |
| JP2010513901A5 (enExample) | ||
| WO2014160275A2 (en) | Biomarkers for liver fibrosis | |
| Li et al. | Anti-PLA2R antibodies in Chinese patients with membranous nephropathy | |
| WO2021076036A1 (en) | Apparatuses and methods for detection of pancreatic cancer | |
| RU2017115663A (ru) | Способы и системы для отличия синдрома раздраженного кишечника от воспалительного заболевания кишечника и глютеновой болезни | |
| US9429569B2 (en) | Peptide and protein biomarkers for type 1 diabetes mellitus | |
| Kuuliala et al. | Constitutive STAT3 phosphorylation in circulating CD4+ T lymphocytes associates with disease activity and treatment response in recent-onset rheumatoid arthritis | |
| JP2017531801A5 (enExample) | ||
| ES2642723B1 (es) | Uso de los niveles de anticuerpos anti-CD26 como biomarcadores de enfermedades autoinmunes y/o inflamatorias. | |
| Zhang et al. | Diagnostic value of hemoglobin and neutrophil-to-lymphocyte ratio in Behcet Disease | |
| Kim et al. | Monoclonal and polyclonal gammopathy measured by serum free light chain and immunofixation subdivide the clinical outcomes of diffuse large B-cell lymphoma according to molecular classification | |
| JP5805518B2 (ja) | マルチプレックス大腸がんマーカーパネル | |
| Concepción et al. | Novel Biomarkers for the diagnosis of diabetic nephropathy | |
| WO2017077105A1 (en) | Method for characterization of cell specific microvesicles | |
| Wang et al. | Different expression of S100A8 in malignant and benign gallbladder diseases | |
| JP2014224759A5 (enExample) | ||
| WO2022184942A2 (en) | Biomarkers | |
| RU2017107273A (ru) | Антилимфоцитарные аутоантитела в качестве диагностических биомаркеров | |
| JP2017528734A5 (enExample) | ||
| JP2020526745A5 (enExample) | ||
| US20170315119A1 (en) | Urinary biomarkers for sle and lupus nephritis | |
| CN111562390A (zh) | 一种神经精神性狼疮的诊断标志物及其检测试剂盒 |